Veneno Technologies, a Tsukuba City, Japan-based Novel DRP Drug Discovery company, raised $2M in Seed funding.
The round was led by SBI Investment, Tsukuba Institute of Research, Ltd., and SBI.
The company intends to use the funds to strengthen the recruitment and organizational structure, to further develop the proprietary peptide drug discovery platform technology, and invest in the research and development of the own drug discovery pipeline using DRP functional peptides as basic molecules to further promote DRP drug discovery.
Veneno Technologies is focused on research and development of peptide DRPs for ion channels, transporters, GPCRs and other membrane proteins. Veneno Suite™ is the company’s proprietary integrated DRP drug discovery technology., which consists of a large gene library that is created by artificially accelerating the evolution of natural DRPs (Disulfide Rich Peptides) using them as templates, a screening system that enables the search for target DRPs from the library in a fast and efficient manner, and technology that enables the efficient production of various DRPs in a short period of time.
FinSMEs
28/01/2022